Related Experiment Video
Updated: Jul 15, 2026
07:09
The Sciatic Nerve Cuffing Model of Neuropathic Pain in Mice
Published on: July 16, 2014
Novel P2X7 receptor antagonists ease the pain
1University College London, Department of Physiology (Hampstead Campus), London, UK. b.king@medsch.ucl.ac.uk
British Journal of Pharmacology
|May 2, 2007
Summary
Novel P2X7 receptor antagonists, like A740003, show promise for treating chronic pain. These selective drugs are effective in both human and animal models, offering new therapeutic avenues.
Area of Science:
- Pharmacology
- Neuroscience
- Drug Discovery
Background:
- The P2X7 receptor is a key target for managing chronic pain.
- Development of selective antagonists is crucial for therapeutic intervention.
- Previous research highlighted the need for potent and specific P2X7 receptor modulators.
Purpose of the Study:
- To review the development and application of novel P2X7 receptor antagonists.
- To explore the role of P2X7 receptors in chronic pain models.
- To assess the potential of these antagonists for human pain relief.
Main Methods:
- Synthesis and characterization of di-substituted tetrazole and cyanoguanidine derivatives.
- Evaluation of antagonist selectivity, stability, potency, and reversibility.
- In vivo studies using animal models to investigate P2X7 receptor involvement in chronic pain.
Main Results:
- Identification of highly selective and potent P2X7 antagonists (e.g., A740003, A438079).
- Demonstration of comparable potency at human and rodent P2X7 receptor isoforms.
- Evidence supporting the role of P2X7 receptors in the onset and persistence of chronic pain in animal models.
Conclusions:
- Novel P2X7 antagonists represent a significant advancement in pain management research.
- These compounds exhibit favorable pharmacological properties for potential therapeutic use.
- Further investigation is warranted to translate these findings into human clinical applications for chronic pain.
Related Concept Videos
01:25Analgesia and Pain Management
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
01:44Nociception
Nociception—the ability to feel pain—is essential for an organism’s survival and overall well-being. Noxious stimuli such as piercing pain from a sharp object, heat from an open flame, or contact with corrosive chemicals are first detected by sensory receptors, called nociceptors, located on nerve endings. Nociceptors express ion channels that convert noxious stimuli into electrical signals. When these signals reach the brain via sensory neurons, they are perceived as pain. Thus, pain helps the...
01:15Opioid Analgesics: Synthetic and Semisynthetic Opioids
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
01:20Pain
Pain serves as a critical warning signal that alerts the body to potential or actual harm. When mechanical pressure on the skin is intense, such as from a sharp pinch, the sensation transitions from touch to pain. Similarly, extreme temperatures, like a hot pot handle, convert the sensation of heat into pain. Pain can also result from overstimulation of other senses, such as blinding light, loud noise, or the intense heat from habañero peppers. This ability to sense pain is essential for...
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
01:25Drug-Receptor Interaction: Agonist
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.